Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2011.1342 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advanced Neuroimaging and Clinical Findings in a Case of Linear Scleroderma En Coup De Sabre Presenting With Seizures.
Cureus
November 2024
Radiology, Grupo CT Scanner, Mexico City, MEX.
Scleroderma is a rare connective tissue disease categorized as systemic or localized. Linear subtype of localized scleroderma usually manifests as a cutaneous linear scar-like lesion most commonly on the scalp. It may present with neurologic, ophthalmologic, and rheumatologic symptoms.
View Article and Find Full Text PDFImiquimod for the treatment of morphea: a systematic review.
Arch Dermatol Res
December 2024
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.
J Clin Med
November 2024
Department of Dermatology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
Morphea, also known as localized scleroderma, is an autoimmune chronic connective tissue disease. It is characterized by excessive collagen deposition in the dermis and/or subcutaneous tissue. The etiopathogenesis of this disease is not fully understood, with endothelial cell damage, immunological disorders, extracellular matrix disorders and factors such as infection, trauma and other autoimmune diseases being considered.
View Article and Find Full Text PDFVascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis.
Front Immunol
December 2024
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.
Introduction: Systemic sclerosis (SSc), a chronic autoimmune condition, is characterized by microvascular dysfunction, ineffective angiogenesis, and fibrosis. The identification of robust biomarkers reflecting these processes may assist in clinical management and lead to the discovery of new therapies. We sought to address this issue by conducting a systematic review and meta-analysis of studies investigating one such biomarker, vascular endothelial growth factor (VEGF), in SSc patients and healthy controls and in SSc patients with localized or diffuse disease, different video capillaroscopy patterns (early, active, or late), and presence or absence of complications.
View Article and Find Full Text PDFBenefits of the Topical JAK Inhibitor Delgocitinib in a Patient With Pediatric Localized Scleroderma.
Pediatr Dermatol
December 2024
Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
This is the first report of pediatric linear scleroderma successfully treated with the topical Janus kinase (JAK) inhibitor delgocitinib. JAK inhibitors targeting the JAK/STAT pathway have been used to treat various immune-mediated diseases. In both in vitro and in vivo, JAK inhibitors also block the transforming growth factor (TGF)-β-mediated effects that contribute to skin sclerosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!